

## FORM 7

### September 2020 - MONTHLY PROGRESS REPORT

Name of Listed Issuer: **Ortho Regenerative Technologies Inc. (the “Company” or the “Issuer”)**

Trading Symbol: **ORTH**

Number of Outstanding Listed Securities: **33 131 236**

Date: **October 5<sup>th</sup>, 2020**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**The Company continued to implement operational initiatives to meet the following business objectives:**

- **The ongoing execution of the FDA required documentation and manufacturing related activities for the filing of a US FDA Investigational New Drug (IND) to test its lead product Ortho-R for rotator cuff tear repair in human following the designation by the FDA Office for Combination Products that Ortho-R is a Drug/Biologic combination product. The jurisdictional assignment for Ortho-R will be the Center for Biologics Evaluation and Research (CBER).**

- The prosecution of its patent families, in prominent world markets.
  - The filing of an application to list the Company's Class A shares on the OTCQB market in the United States. The listing of the Company's Shares on the OTCQB remains subject to the Company fulfilling all the listing requirements of the OTCQB and any other regulatory requirements. The Company will continue to maintain the listing of its Shares on the CSE under the symbol "ORTH".
2. Provide a general overview and discussion of the activities of management.

**During the period, Management's focus was to:**

- (i) Continue cGMP clinical batch manufacturing activities prior to filing a US FDA IND to test Ortho-R for rotator cuff tear repair in human;
  - (ii) Develop and finalize the Clinical study protocol for ORTHO-R, our lead program for rotator cuff tear repair;
    - a. MCRA, the company's US based orthopaedic specialty clinical research organization ("CRO") selected to conduct its upcoming rotator cuff tear repair Ortho-R human trial, and the Ortho Team continued working together on regulatory and clinical planning activities, including the clinical protocol, identification of investigators and clinical testing sites, and more.
  - (iii) Execute any required research and development, regulatory, manufacturing, or operational activities required to support the above initiatives, either internally or through the company's partners and key suppliers;
  - (iv) Actively promote itself to strategic partners interested in our biopolymer technology and/or active programs; and
  - (v) Actively promote itself to potential institutional and retail investors as well as healthcare-life science investment bankers and analysts to facilitate raising the capital required to fund its operations and upcoming clinical programs.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
- Nothing applicable during the period.**
4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.
- Nothing applicable during the period.**
5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**Nothing applicable during the period**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**Nothing applicable during the period.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**Nothing applicable during the period.**

8. Describe the acquisition of new customers or loss of customers.

**Nothing applicable during the period.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks

**Nothing applicable during the period.**

10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

**Nothing applicable during the period**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**Nothing applicable during the period.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**Nothing applicable during the period.**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**The Company closed a \$137,600 additional non-brokered private placement of units (the "Private Placement"). The additional Private Placement was conducted at the same terms and follows the closing of a non-brokered and oversubscribed \$2.5 million private placement of units completed on August 21, 2020 bringing the overall gross proceeds raised through the two private placements to \$2.6 million.**

**The Company issued an additional 430,000 units (the "Units") at a purchase price of \$0.32 per Unit for total gross proceeds of \$137,600. Each Unit consists of one (1) class A share of the Company (a "Share") and one (1) Share purchase warrant of the Company (a "Warrant"). Each Warrant is exercisable into one (1) Share in the capital of the Company (a "Warrant Share") at the price of \$0.50 per Warrant Share for a period of 36 months from closing. In the event that the daily VWAP over any twenty (20) consecutive trading days is greater or equal to \$1.00, the Company may give notice to the Warrant holder, at any time after February 5, 2021, that all remaining Warrants must be exercised within a period of 30-days from the date of receipt of the notice, failing which the Warrants will automatically expire. The "VWAP" is the average of the volume weighted average market price of the Company's Common Shares on a single day.**

The Common Shares and the Warrants issued under the Private Placement are subject to a statutory 4-months hold period under the applicable securities laws and in such case the certificates evidencing the Shares and the Warrants will bear a legend to that effect, as applicable. No broker or agent was involved in the transaction.

The net proceeds from the additional Private Placement will be used to fund the following ongoing value creation activities: 1) Securing FDA's approval to start our US clinical trial on ORTHO-R for rotator cuff tear repair 2) Manufacturing GMP Clinical Trial batch for Ortho-R 3) Completing US clinical trial investigation sites selection, setting, and training 4) Starting US clinical trial patients enrolment activities 5) Secure US exchange listing for Ortho RTI's shares 6) General and administrative corporate purposes.

14. Provide details of any securities issued and options or warrants granted.

The Company issued an aggregate of 65,000 stock options to two consultants. The stock options have an exercise price of \$0.63 and vest over 3 years, with a maturity date of 8 years after the grant. The pricing and vesting terms of the options were set in accordance with the Company's Share Option Plan.

15. Provide details of any loans to or by Related Persons.

**Nothing applicable during the period.**

16. Provide details of any changes in directors, officers or committee members.

**Nothing applicable during the period**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The outbreak of a novel strain of the coronavirus, ("COVID-19"), has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures have caused material disruption to businesses globally resulting in an economic slowdown which may impact some of the operational initiatives we are currently pursuing in order to meet our business objectives. Those initiatives include planning activities for the filing of a US FDA IDE, completing the pre-clinical histology samples analysis final report, continuing cGMP manufacturing scale up activities, executing the ORTHO-R Clinical study plan for rotator cuff repair and our ability to timely secure access to supplies. As of today, we have been mildly impacted by the COVID-19 outbreak and we continue to interact with the scientific, medical and financial communities to mitigate as best as possible any impact that could affect negatively our timelines. Our employees, their families as well as our outsourced collaborators are the most important assets we have, and we are taking all actions to protect and accommodate them during these challenging times.

## Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All the information in this Form 7 Monthly Progress Report is true.

Dated: October 5th, 2020

Ortho Regenerative Technologies Inc.  
*/s/ Luc Mainville*  
Senior VP & Chief Financial Officer  
Official Capacity

<b><i>Issuer Details</i></b>	For Month End	Date of Report
Name of Issuer Ortho Regenerative Technologies Inc.	September 2020	YY/MM/D 2020/10/05
Issuer Address 16667, Boul. Hymus,		
City/Province/Postal Code Kirkland, Quebec, H9H 4R9	Issuer Fax No. 514.694.0443	Issuer Telephone No. 514.694.0865
Contact Name Luc Mainville	Contact Position Sr. VP & CFO	Contact Telephone No. (514) 693-8854
Contact Email Address mainville@orthorti.com	Web Site Address <a href="http://www.orthorti.com">www.orthorti.com</a>	